2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro-

Quabodepistat (OPC-167832) (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokineticcharacteristic. The plasma reaches peak at 0.5 h to 1.0 h (t_max) and is eliminated with a half-life (t_1/2) of 1.3 h to 2.1 hQuabodepistat distribution in the lungs is approximately 2 times higher than that in plasma, and theC_maxand AUC_t of Quabodepistat in plasma and the lungs shows dose dependency^[1].Quabodepistat (oral administration; 0.625-10 mg/kg; 4weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625mg/kg to 2.5mg/kg. In aM. tuberculosisKurono-infected ICR female mice model. Quabodepistat combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone^[1].^[1].Quabodepistat (oral gavage; 2.5mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate^[1].